Home » Newsletters » BioWorld Science

BioWorld Science

July 23, 2007

View Archived Issues

Recent patents impart new therapeutic agents for cancer

Recent Bristol-Myers Squibb patent describes new agents for thrombotic disorders

Mechanism behind orlistat's antitumor activity explored

New compounds targeting autoimmune diseases claimed in recent Mitsubishi Pharma patent

pSivida reflects on transition to drug delivery company

Fast track designation for Generx

Enrollment open in women-only drug-eluting stent trial

TAK-491 enters phase III in U.S. and Europe

Antares Pharma and Jazz sign product development and license agreement

GeoVax begins two new AIDS vaccine clinical trials

Salix submits NDA for twice daily antiinflammatory balsalazide

Cortex to resume Alzheimer-PET scan study with higher dose levels

Roche and Trimeris begin integrase inhibitor and once-daily Fuzeon combination trial

Avastin recommended for E.U. approval in NSCLC

Celsentri recommended for approval in E.U.

Sugammadex MAA accepted for review

Galvus receives European recommendation for approval

CHMP recommends E.U. approval of Aclasta for postmenopausal osteoporosis

Exelon Patch recommended for E.U. approval

Yondelis recommended for E.U. approval in soft tissue sarcoma

EMEA recommends approval for Merz's Xeomin

LG Life Sciences synthesizes novel, potent DPP-IV inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...